Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia — A Single-Center Experience from the GCC Region
Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32
DOI: 10.1177/10760296261439468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 20.04.2026. Verfasst von Shehab F Mohamed und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Thrombosis, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Thrombosis remains a clinically important complication of acute promyelocytic leukemia (APL), coexisting with the prototypical hemorrhagic diathesis. Data from Gulf Cooperation Council (GCC) populations are limited in addition to data specifically about thrombosis, which is heterogenous in general.
Objectives
To describe the incidence, clinical characteristics, treatment, and outcomes of thrombotic events in patients with APL treated at a tertiary center in the GCC.
Methods
We conducted a retrospective cohort study of 75 consecutive patients with newly diagnosed APL managed at a single tertiary center. Baseline demographic variables (age, sex, regional background), hematologic parameters (hemoglobin, leukocyte, platelet counts), and coagulation indices (fibrinogen, activated partial thromboplastin time, prothrombin time, international normalized ratio, and D-dimer) were compared between patients with and without thrombosis. Thrombotic event type, timing, antithrombotic management, bleeding complications, and mortality (including early mortality within 30 days) were recorded.
Results
Eleven of 75 patients (14.7%) developed thrombosis. Baseline demographic characteristics, hemoglobin level, leukocyte count, platelet count, fibrinogen, and activated partial thromboplastin time were comparable between patients with and without thrombosis, whereas prothrombin time, international normalized ratio, and D-dimer levels were numerically higher in patients who developed thrombosis. Most thrombotic events (73%) occurred during active therapy, and the majority were venous (55%). Pulmonary embolism accounted for 36% of all thrombotic episodes, and catheter-associated thromboses represented a clinically relevant subset. Anticoagulation was initiated in 45% of patients with thrombosis and antiplatelet therapy in 18%. Bleeding episodes occurred in 36% of patients who experienced thrombosis. Thrombosis was associated with a 27% all-cause mortality.
Conclusions
In this GCC APL cohort, thrombosis, though less frequent than bleeding, emerged as a serious and clinically significant manifestation associated with substantial morbidity and mortality. These findings underscore the need for vigilant thrombo-hemorrhagic assessment and individualized antithrombotic strategies, particularly during induction and early consolidation therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
- Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
- Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
- Department of Laboratory Medicine & Pathology, Hematopathology Division, Hamad Medical Corporation, Doha, Qatar.
- College of Medicine, Qatar University, Doha, Qatar.
ORCID-Profile: Rafal AlShebly, Mohammed Abdulgayoom, Abdulrahman F Al-Mashdali, Maritta Rabadi
Zitieren
APA
Mohamed, S. F., AlShebly, R., Shawaylia, H., Elahie, A., Ghasoub, R., Soliman, D., Mudawi, D., Abdulgayoom, M., Al-Mashdali, A. F., Rabadi, M., El-Sabah, H., Hamad, A., Yassin, M., & Cherif, H. (2026). Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia — A Single-Center Experience from the GCC Region. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261439468
Vancouver
Mohamed SF, AlShebly R, Shawaylia H, Elahie A, Ghasoub R, Soliman D, et al. Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia — A Single-Center Experience from the GCC Region. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261439468
BibTeX
@article{Mohamed2026,
author = {Mohamed, Shehab F and AlShebly, Rafal and Shawaylia, Hawraa and Elahie, Anil and Ghasoub, Rola and Soliman, Dina and Mudawi, Deen and Abdulgayoom, Mohammed and Al-Mashdali, Abdulrahman F and Rabadi, Maritta and El-Sabah, Hesham and Hamad, Anas and Yassin, Mohamed and Cherif, Honar},
title = {Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia — A Single-Center Experience from the GCC Region},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
volume = {32},
doi = {10.1177/10760296261439468}
}
EUVIMED